{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-097575","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.943575+00:00","generated_at":"2026-05-15T17:56:06.921324+00:00","sec_items":["1.01","2.02","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Korro Bio raises $85M in PIPE led by Venrock; cash runway into H2 2028","bullets":["Gross proceeds ~$85M from 4,501,928 shares at $11.11 and 3,148,836 pre-funded warrants at $11.109.","Preliminary cash, equivalents, marketable securities of $85.2M as of Dec 31, 2025; runway through H2 2028.","Proceeds fund clinical milestones: KRRO-121 for urea cycle disorders and GalNAc-conjugated AATD program.","Closing expected March 10, 2026; placement agents include Citigroup, Cantor, Oppenheimer, William Blair."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-097575","json":"https://secwatch.observer/filing/0001193125-26-097575.json","markdown":"https://secwatch.observer/filing/0001193125-26-097575.md","text":"https://secwatch.observer/filing/0001193125-26-097575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/0001193125-26-097575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/krro-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:56:06.921324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1fdf2adeeb4351935bb591787bfbbe86182d624c","claim":"Korro Bio, Inc. entered into subscription agreement with a number of institutional accredited investors valued at approximately $85.0 million (effective 2026-03-09).","evidence_excerpt":"Korro Bio, Inc., or Korro, entered into a subscription agreement with a number of institutional accredited investors pursuant to which it agreed to sell and issue in a private placement","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312526097575/0001193125-26-097575-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"a number of institutional accredited investors"},{"label":"Value","value":"approximately $85.0 million"},{"label":"Effective","value":"2026-03-09"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}